Results 61 to 70 of about 1,117 (151)

Establishing the Safety and Efficacy of Bedaquiline‐Containing Regimen for the Treatment of Drug‐Resistant Tuberculosis: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials

Pulmonary Medicine, Volume 2024, Issue 1, 2024.
The risks and benefits of bedaquiline (BDQ) for treatment of drug‐resistant tuberculosis (DR‐TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ‐containing regimens for the treatment of DR‐TB as evidenced in available randomized controlled trials (RCTs).
Muhammad Candragupta Jihwaprani, Yipeng Sun, Wahyu Choirur Rizky, Idris Sula, Nazmus Saquib, Laura Pini   +5 more
wiley   +1 more source

Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects

Antimicrobial Agents and Chemotherapy
ABSTRACT TBAJ-876, a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile compared with bedaquiline, is under development for the treatment of drug-susceptible and drug-resistant tuberculosis (TB). A phase 1, first-in-human study of TBAJ-876,
Antonio Lombardi, Fran Pappas, Jerry Nedelman, Dean Hickman, Sarah Jaw-Tsai, Morounfolu Olugbosi, Paul Bruinenberg, Maria Beumont, Eugene Sun   +8 more
openaire   +2 more sources

Structural basis for inhibition of mycobacterial ATP synthase by squaramides and second generation diarylquinolines

bioRxiv, 2023
G. M. Courbon, Paul R. Palme, Lea Mann, A. Richter, P. Imming, J. Rubinstein   +5 more
semanticscholar   +1 more source

TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug’s Uncoupler Activity

Antimicrobial Agents and Chemotherapy, 2019
The diarylquinoline F1FO-ATP synthase inhibitor bedaquiline (BDQ) displays protonophore activity. Thus, uncoupling electron transport from ATP synthesis appears to be a second mechanism of action of this antimycobacterial drug. Here, we show that the new
J. Sarathy, P. Ragunathan, Christopher B. Cooper, A. Upton, G. Grüber, T. Dick   +5 more
semanticscholar   +1 more source

Synthesis and trypanocidal activity of substituted 2,4-diarylquinoline derivatives

Arkivoc, 2021
Kola A. Oluwafemi, Siyolise Phunguphungu, Sinalo Gqunu, Michelle Isaacs, Heinrich C. Hoppe, Rosalyn Klein, Perry T. Kaye   +6 more
openaire   +2 more sources

The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance

bioRxiv
Cavitary tuberculosis (TB) is difficult to cure and a site of relapse. Bedaquiline has been a wonder drug in the treatment of multidrug resistant TB, but emergence of resistance threatens its sustained success.
Annamarie E. Bustion, Jacqueline P. Ernest, Firat Kaya, Connie Silva, Jansy P. Sarathy, L. Blanc, Marjorie Imperial, M. Gengenbacher, Minli Xie, Matthew D. Zimmerman, G. T. Robertson, Danielle M. Weiner, Laura E Via, Clifton E. Barry, R. Savic, Véronique A. Dartois   +15 more
semanticscholar   +1 more source

Bedaquiline reloading strategies following interruptions during daily dosing. [PDF]

Antimicrob Agents Chemother
Kikstra N, Beek SWv, Maartens G, Brust JCM, Svensson EM, Koele SE.   +5 more
europepmc   +1 more source

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination. [PDF]

Front Tuberc
Moonan PK, Holtz TH.
europepmc   +1 more source

S1.9 ATP synthase as target of the tuberculosis antibiotic diarylquinoline

Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2008
Ristic, Zorica, Haagsma, Anna C., Lill, Holger, Bald, Dirk, Koul, Anil, Vergauwen, Karen, Andries, Koen   +6 more
openaire   +1 more source

Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study. [PDF]

Antimicrob Agents Chemother
Darpo B, Nedelman J, Bruning-Barry R, Hickman D, Kleiman R, Lombardi A, Xue H.   +6 more
europepmc   +1 more source